Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438027 | 0.80 | CYP3A4 (0.42) | CYP11B1CYP11B2NPC1RAB9AALDH1A1 | |
| SCHEMBL9387335 | 0.80 | RAB9A (0.42) | HDAC6NPC1RAB9AALDH1A1HSD17B1 | |
| SCHEMBL987523 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2HDAC6NOTUMNPC1 | |
| SCHEMBL6375451 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2HDAC6NOTUMNPC1 | |
| SCHEMBL12531530 | 0.79 | CYP11B1 (0.49) | CYP11B1CYP11B2HDAC6NPC1RAB9A | |
| SCHEMBL10899166 | 0.79 | PTGS1 (0.50) | CYP11B1CYP11B2HDAC6NPC1RAB9A | |
| SCHEMBL2600215 | 0.76 | ALDH1A1 (0.50) | CYP11B1CYP11B2HDAC6NPC1RAB9A | |
| SCHEMBL9454086 | 0.76 | CYP2A6 (0.42) | CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL20604117 | 0.76 | FFAR1 (0.53) | CYP11B1CYP11B2HDAC6RAB9AALDH1A1 | |
| SCHEMBL38655961 | 0.76 | CNR1 (0.42) | NPC1RAB9AALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| CN-102026961-A | Amide compound | ASTELLAS PHARMA INC | 2011-04-20 | — | — | CN | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-7342116-B2 | Process for producing heterocyclic aldehyde | KOEI CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-0032432-B1 | PROSTANOID COMPOUNDS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 1985-07-24 | — | — | EP | disclosed |
| US-4438111-A | PROSTAGLANDINS, ANTICOAGULANTS, ANTIASTHMA | GLAXO GROUP LIMITED (GB) | 1984-03-20 | — | — | US | disclosed |
| US-4327092-A | USEFUL AS ANTICOAGULANTS AND ANTI-HISTAMINES | GLAXO GROUP LIMITED (GB) | 1982-04-27 | — | — | US | disclosed |
| EP-0032432-A1 | Prostanoid compounds and their preparation and pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 1981-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | CYP11B1 80/4885CYP11B2 50/4885HDAC6 4524/4885 |
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | CYP11B1 3162/4885CYP11B2 2632/4885HDAC6 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.